Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome II plus cetuximab in third-line or later metastatic colorectal cancer
ChiCTR2600118261Phase 4Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Irinotecan liposome II and cetuximab in metastatic colon cancer (mCRC), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Objective response rate (ORR). Planned start Feb 2026; status: not yet recruiting.
02
Drugs
Irinotecan liposome IIcetuximab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on ChiCTR2600118261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118261.